MedTrace Logo

Exemestane With Sunitinib (SUTENT®) in Metastatic Breast Cancer

NCT00905021 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 4

Last updated 2020-07-24

Study results available
· View outcomes & findings →

Summary

The investigators want to find out if the treatments used in this study are helpful to patients that are diagnosed with hormone receptor positive metastatic breast cancer. The investigators want to also look at any side effects that could happen while patients are on the study treatments. The investigators want to see if there are any changes that could show us if your cancer is responding to the study treatments.

Conditions

Interventions

DRUG

Exemestane

Exemestane 25 mg by mouth every day.

DRUG

Sutent

Sunitinib 37.5 mg by mouth every day.

Sponsors & Collaborators

  • Pfizer

    collaborator INDUSTRY

  • Baylor Breast Care Center

    lead OTHER

Principal Investigators

  • Mothaffar Rimiawi, MD · Baylor College of Medicine

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-03-31
Primary Completion
2011-01-31
Completion
2012-02-29

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00905021 on ClinicalTrials.gov